Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07312734 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Enable New Diagnostics for Pulmonary Microbes in People With CF

Study acronym: SEND-CF
StatusRecruiting
PhaseNot specified
SponsorChris Goss
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened
    • Start date changed from estimate of Feb 1, 2026 to Mar 30, 2026
    • Site details revised at 9 of 9 sites
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Sputum culture has been the best approach to detect harmful bacteria in the lungs of people with cystic fibrosis (CF). With the widespread use of new CF therapies (like Trikafta and Alyftrak), it is more difficult for people with CF to produce sputum even though they still have harmful bacteria in their lungs. The SEND-CF study is being done to see if there are other ways to detect harmful bacteria in the lungs.
Trial Details
NCT Number NCT07312734
Lead Sponsor Chris Goss
Collaborators: Cystic Fibrosis Foundation, University of Pennsylvania
Conditions
(from sponsor)		 Cystic Fibrosis (CF), New Diagnostics
Related terms Cystic Fibrosis
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov